Celldex Therapeutics diskutieren
Celldex Therapeutics
WKN: A2PEAB / Symbol: CLDX / Name: Celldex / Aktie / Biotechnologie & medizinische Forschung / Micro Cap /
33,80 €
-1,73 %
bevor sie davon läuft
SecteurRecherche biotechnologique et médicale Agenda 06/11 Publication de résultats
Develops and commercialization of immunotherapy technologies for the treatment of cancer and other diseases
Celldex Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products.
Its portfolio includes therapeutic antibodies, antibody drug conjugates, vaccines, and immune system modulators.
The company's drug candidates include Glembatumumab vedotin, Varlilumab, CDX-1401, CDX-301, and Rintega.
Celldex Therapeutics was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
Celldex Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products.
Its portfolio includes therapeutic antibodies, antibody drug conjugates, vaccines, and immune system modulators.
The company's drug candidates include Glembatumumab vedotin, Varlilumab, CDX-1401, CDX-301, and Rintega.
Celldex Therapeutics was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
Nombre d'employés : 197 personnes.
(Vom Mitglied beendet)
Geht
hier was?
SecteurRecherche biotechnologique et médicale
Nombre d'employés : 197 personnes
(Stop Loss Kurs erreicht)
Neueinstieg
nach Stopploss.
(Laufzeit überschritten)
(Stop Loss Kurs erreicht)
Buy closed
Sell mit Kursziel 1,0
Buy mit Kursziel 3,0
Buy Celldex Therapeutics
Buy Celldex Therapeutics
Buy Celldex Therapeutics
Buy Celldex Therapeutics
Sell Celldex Therapeutics
Sell mit Kursziel 6,0
Sell Celldex Therapeutics
Sell mit Kursziel 7,0
Neueste Beiträge
quelbe60 in Adaptimmune Therapeutics PLC ADR diskutieren